Radequinil

Chemical compound
  • None
Identifiers
  • 5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
CAS Number
  • 219846-31-8
PubChem CID
  • 22714308
ChemSpider
  • 11584471
UNII
  • 2G222T03EY
CompTox Dashboard (EPA)
  • DTXSID60944577 Edit this at Wikidata
Chemical and physical dataFormulaC18H14N4O3Molar mass334.335 g·mol−13D model (JSmol)
  • Interactive image
  • COc1cccc(c1)c3nccc2NC(=O)\C(=C/c23)c4nc(C)on4
InChI
  • InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23)
  • Key:JQOFKKWHXGQABB-UHFFFAOYSA-N

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]

See also

  • GABAA receptor negative allosteric modulator
  • GABAA receptor § Ligands

References

  1. ^ a b Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer's Disease" (PDF). The Open Neuropsychopharmacology Journal. 1: 19–23. doi:10.2174/1876523800801010019.
  2. ^ Pogacić V, Herrling P (2007). "List of drugs in development for neurodegenerative diseases. Update June 2007". Neuro-Degenerative Diseases. 4 (6): 443–86. doi:10.1159/000107705. PMID 17934328.
  • v
  • t
  • e
GABA receptor modulators
Ionotropic
GABAATooltip γ-Aminobutyric acid A receptor
GABAATooltip γ-Aminobutyric acid A-rho receptor
Metabotropic
GABABTooltip γ-Aminobutyric acid B receptor
See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e